GE HealthCare (GEHC): Imaging and Dx Drive the Case
GE HealthCare is gaining traction from strong imaging and pharmaceutical diagnostics growth, but Patient Care Solutions remains a drag. The stock looks fairly valued with a Hold rating and a $76 fair value estimate.
GE HealthCare Technologies Inc. (GEHC) is a Hold and is earning an overall grade of B, making it a reasonable but not compelling buy right now. The company’s imaging and diagnostics businesses are performing well, but Patient Care Solutions execution and balance sheet risk keep the setup balanced. Our fair value is $76.
Thesis
GE HealthCare Technologies Inc. (GEHC) offers a credible medium-term investment case built on strong imaging franchises, fast-growing Pharmaceutical Diagnostics, recurring service revenue, and a growing AI and software layer. The company reported $5.3B of revenue in the second quarter of 2026, 3.5% organic growth, 11.1% organic orders growth, a 1.15x book-to-bill ratio, and a record $23.9B backlog.
The central strength is operating momentum outside Patient Care Solutions. Advanced Imaging Solutions generated $3.8B of second-quarter revenue with a 13.9% EBIT margin, while Pharmaceutical Diagnostics delivered $843M of revenue, 14.6% organic growth, and a 29.6% EBIT margin. Patient Care Solutions generated $675M of revenue, down 13.5% organically, and posted a negative 3.8% EBIT margin.
At a quoted share price of $71.98, GEHC trades at 16.3x trailing earnings and 13.2x forward earnings. The valuation is reasonable for a business with 16.8% earnings growth, a 7.7% free cash flow yield, and analyst targets centered at $82.70, but the balance sheet and PCS execution keep the risk profile above that of a pristine defensive compounder. The recommendation is Hold, with a fair value estimate of $76.00.
Company Overview
GEHC is a global healthcare technology company headquartered in Chicago and listed on Nasdaq. The company develops, manufactures, and markets medical imaging systems, patient care devices, pharmaceutical diagnostics, services, and AI-enabled software. Its products serve hospitals, health systems, researchers, and public, private, academic, and government institutions in more than 160 countries.
The business has approximately 54,000 employees, 9,700 sales professionals, and 8,900 field service engineers. That commercial and service footprint matters in medical technology because hospital purchases depend on installation, uptime, clinical training, maintenance, and compatibility with existing equipment.
▌Common Questions
Frequently asked questions
+Is GEHC stock a buy right now?
GEHC is not a clear Buy right now; it is rated Hold because the upside from imaging and pharmaceutical diagnostics is offset by Patient Care Solutions weakness and balance sheet risk. The business is improving, but the current setup looks fairly valued rather than deeply discounted.
+What is GEHC's fair value?
GEHC's fair value is $76. We arrive there by weighing its 13.2x forward earnings multiple, 16.8% earnings growth, 7.7% free cash flow yield, and the fact that analyst targets center around $82.70, while still discounting for PCS execution risk and a less-than-pristine balance sheet.
+
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
The 2026 reporting structure combines Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions, alongside Patient Care Solutions and Pharmaceutical Diagnostics. The broader portfolio still spans CT, MR, X-ray, molecular imaging, ultrasound, interventional systems, monitoring, anesthesia, maternal-infant care, contrast media, and radiopharmaceuticals.
Business Segment Deep Dive
Advanced Imaging Solutions is the company’s core engine. Second-quarter revenue reached $3.8B, up 5.0% organically, and segment EBIT margin expanded 90 basis points to 13.9%. Growth came from cardiovascular and interventional solutions, CT, and molecular imaging. The segment also benefited from volume and pricing, which offset part of the pressure from cost inflation.
Pharmaceutical Diagnostics is the portfolio’s highest-margin growth asset. Second-quarter revenue rose 14.6% organically to $843M, while EBIT margin reached 29.6%. Contrast media benefited from volume and pricing, and U.S. radiopharmaceutical growth added another structural driver. This mix gives GEHC exposure to recurring diagnostic procedures rather than only periodic hospital equipment purchases.
Patient Care Solutions is the clear weak link. Revenue declined 13.5% organically to $675M, and segment EBIT was negative $26M. Management attributed the result to fulfillment and manufacturing challenges affecting monitoring and anesthesia products. Strong first-half orders growth in monitoring and international premium anesthesia demand provide evidence of customer interest, but the second-quarter loss shows that demand has not yet translated into reliable execution.
The segment mix is gradually moving toward businesses with better growth and margin characteristics. PDx posted a 29.6% EBIT margin in the latest quarter, while AIS expanded margin despite inflation. A successful PCS recovery would add operating leverage, but the current investment case does not require PCS to become a major growth contributor immediately.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Photonova Spectra, GEHC’s photon-counting CT platform, is a flagship example of the company’s push toward higher-value imaging. Management reported strong U.S. customer interest and expects CE marking in the second half of 2026, expanding the product’s European opportunity.
True Definition DL adds a second layer of value by upgrading the installed CT base. Management said the deep-learning software nearly doubles image resolution and is offered through a subscription model. That combination matters because GEHC can monetize existing systems without relying entirely on a new scanner sale.
The product strategy extends beyond CT. Vivid Pioneer ultrasound uses a common platform to lower manufacturing cost while adding AI capabilities that support higher pricing. In Pharmaceutical Diagnostics, Flyrcado reached 545 doses for the week ended July 24, about 40% above April levels, and management retained its target of at least $500M in annual Flyrcado revenue by 2028.
Innovation & Competitive Advantage
GEHC’s innovation advantage comes from combining hardware, pharmaceuticals, services, and software. The 2026 10-K identifies approximately 11,100 engineers and scientists worldwide. That research base supports medical devices, clinical applications, AI tools, cloud systems, and product upgrades across the installed base.
The D3 strategy is designed to sell solutions around disease states rather than isolated products. Heartbeat, GEHC’s operating system, connects customer needs, product development, sales, and service. The second-quarter orders result provides tangible evidence that this commercial redesign is gaining traction, with broad contributions from ultrasound, MR, CT, patient monitoring, radiopharmaceuticals, and interventional labs.
The company’s intellectual property portfolio, clinical expertise, installed base, and service network reinforce one another. GEHC also reported 100 FDA AI authorizations in 2025, showing meaningful product activity in a rapidly expanding field. AI is valuable here when it improves workflow, image quality, throughput, or pricing, rather than simply decorating an investor presentation.
Operations & Supply Chain
GEHC operates manufacturing, assembly, and pharmaceutical production across 44 facilities in 17 countries. Its supply chain uses regional production, diversified sourcing, buffer capacity, and risk-focused analytics. The model is especially important in Pharmaceutical Diagnostics, where a supply interruption can delay or cancel patient examinations.
Execution remains uneven. PCS suffered fulfillment problems in the second quarter, while company-wide adjusted EBIT margin fell 40 basis points year over year to 14.2%. Management cited memory chips, oil, freight, and other component inflation as cost pressures. Price and cost actions began contributing in the second quarter, with a larger contribution planned for the second half of 2026 and 2027.
The Intelerad acquisition, completed on March 18, 2026, for a $2.3B cash base purchase price, expands GEHC’s cloud PACS, image sharing, workflow orchestration, and AI capabilities. The strategic logic is strong, but the purchase also raises integration demands at a time when PCS already requires management attention.
The record $23.9B backlog and 1.15x book-to-bill ratio give operations a substantial revenue base to convert. The quality of that backlog depends on shipment execution, service delivery, and working-capital discipline. Second-quarter free cash flow of $68M, after $617M of negative free cash flow in the quarterly financial statements, illustrates how operational timing can affect reported cash generation.
Market Analysis
GEHC operates in a large and growing medical technology market. MarketsandMarkets estimates the global MedTech industry at $694.7B in 2025, while BCC Research estimates the broader medical devices market at $810.4B in 2024 and $1.3T by 2029. The differing estimates reflect market definitions, but both figures show the scale of the opportunity.
Demand is supported by an aging population, chronic disease, diagnostic intensity, and care delivery constraints. The World Health Organization projects that 1.4 billion people will be aged 60 or older by 2030. Hospitals are also investing in equipment and software that can increase throughput when skilled labor is scarce.
AI, cloud connectivity, remote monitoring, and workflow automation are shifting value from standalone devices toward integrated platforms. GEHC’s True Definition DL, CareIntellect, Intelerad, and AI-enabled ultrasound products align with this transition. The FDA reported more than 1,600 authorized AI-enabled medical devices by September 2026, making innovation cadence a competitive requirement rather than a novelty.
The market also has real constraints. Gartner has identified fiscal and workforce pressure at healthcare providers, conditions that can lengthen capital equipment sales cycles. GEHC’s 2026 guidance of 3.0% to 4.0% organic sales growth reflects a measured outlook rather than a boom assumption.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
GEHC sells primarily to hospitals, integrated health systems, imaging centers, outpatient providers, researchers, and government institutions. Customers purchase through a mix of equipment contracts, service agreements, consumables, diagnostic agents, software subscriptions, and enterprise collaborations.
The company’s commercial model includes direct sales teams, regional teams, strategic account executives, virtual sales, and more than 5,000 indirect third-party partners. Its 8,900 field service engineers support an installed base where uptime, training, and maintenance are central to customer economics.
GEHC’s approximately $500M agreement with Catholic Health in New York illustrates the enterprise model. The arrangement combines Vivid Pioneer ultrasound, the Allia interventional platform, digital tools, service, and process expertise. The University Hospital Essen collaboration similarly combines cyclotrons, Total Body PET, SPECT/CT systems, and MIM software around oncology and theranostics.
Competitive Landscape
GEHC’s 2026 10-K names Siemens Healthineers, Philips Healthcare, United Imaging, Mindray, and Canon as primary global competitors. In Pharmaceutical Diagnostics, the named competitors include Bayer, Bracco, Guerbet, and Curium.
Competition rests on product performance, clinical quality, safety, delivery speed, service, software, innovation, and brand reputation. GEHC’s strongest defense is the combination of a broad portfolio and global service reach. Hospitals can standardize equipment, train staff, connect data, and negotiate enterprise service through one major supplier.
The company still faces serious pressure from Siemens Healthineers and Philips in imaging, monitoring, and workflow solutions. United Imaging and Mindray are important competitors in price-sensitive markets, while Canon remains relevant across imaging. In China, GEHC’s filing identifies local competition and volume-based procurement as pressure points.
GEHC’s competitive position is improving where AI raises the value of the installed base and where PDx products support recurring procedures. The second-quarter AIS margin expansion and PDx growth support that view. PCS, however, shows that a broad product portfolio can also create more operational surfaces for competitors to exploit.
Macro & Geopolitical Landscape
GEHC is exposed to hospital capital budgets, reimbursement policy, trade restrictions, foreign exchange, and global regulation. The second quarter included $23M of adjusted EBIT benefit from IEEPA tariff refunds, while management also cited inflation in memory chips, oil, and freight. That combination shows how policy and input costs can move margins even when customer demand remains healthy.
China represents both a market opportunity and a geopolitical risk. GEHC’s 10-K identifies local competition, volume-based procurement, and policy developments in China as factors affecting orders and revenue. Pricing pressure in that market can limit the benefit of global equipment demand.
Regulatory requirements are extensive across medical devices, pharmaceuticals, AI, and patient data. GEHC must comply with FDA, European, Chinese, and other national rules covering product safety, quality, clinical evidence, cybersecurity, privacy, and post-market monitoring. The FDA’s Quality Management System Regulation became effective on February 2, 2026, adding to the compliance workload for device manufacturers.
The macro setting favors products that reduce labor requirements or improve hospital throughput, but it does not remove budget discipline. GEHC’s record orders growth of 11.1% and reaffirmed 2026 guidance show resilience, while the PCS decline and lower quarterly cash flow show that macro pressure still reaches the income statement.
Balance Sheet Health
▌Premium Members Only
Net debt stands at $7.0B with a 2.2x net leverage ratio, leaving GEHC with enough flexibility but not the fortress balance sheet of a top-tier defensive name.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Second-quarter revenue rose to $5.3B with 3.5% organic growth, while Advanced Imaging and Pharmaceutical Diagnostics delivered 13.9% and 29.6% EBIT margins, respectively.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Analysts are looking for 16.8% earnings growth, supported by a 1.15x book-to-bill ratio, $23.9B of backlog, and continued strength in higher-margin diagnostics.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
GEHC is a solid healthcare technology franchise with a favorable mix of imaging, pharmaceutical diagnostics, services, and AI-enabled software. The second-quarter data show genuine demand strength, with 11.1% organic orders growth, a 1.15x book-to-bill ratio, and a record backlog.
The investment debate is concentrated in execution. AIS and PDx are producing the strongest evidence, while PCS remains a drag on revenue, margins, and confidence. The balance sheet is manageable, but $10.1B of debt and volatile quarterly cash flow argue for discipline rather than aggressive positioning.
At $71.98, the shares offer quality at a reasonable price, not an obvious bargain. A medium-term investor can justify ownership for the diagnostic growth pipeline and installed-base economics, but the Hold recommendation remains appropriate until PCS execution and cash conversion provide a stronger margin of safety.
Why is GE HealthCare rated Hold instead of Buy?
The stock deserves a Hold because the strongest parts of the portfolio are already reflected in the valuation, while PCS is still posting a negative 3.8% EBIT margin and a 13.5% organic revenue decline. That mix leaves GEHC with solid fundamentals, but not enough margin of safety for a Buy.
+Which GEHC business segments are driving growth?
Advanced Imaging Solutions and Pharmaceutical Diagnostics are doing the heavy lifting. AIS generated $3.8B of revenue with a 13.9% EBIT margin, while PDx posted $843M of revenue, 14.6% organic growth, and a 29.6% EBIT margin.
+What is the biggest risk for GEHC investors?
The biggest risk is that Patient Care Solutions continues to underperform, since it produced a $26M EBIT loss in the latest quarter after fulfillment and manufacturing issues. If that segment does not stabilize, it can limit margin expansion even if imaging and diagnostics keep improving.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.